£195M
M&G Investments contributed £35m to the £195m private transaction alongside Temasek, Wellington Management, and Nikon.
Oxford Nanopore Technologies
Oxford Nanopore Technologies develops DNA and RNA sequencing systems for scientific research and public health.
£309MTotal raised
Oxford Nanopore Technologies develops DNA and RNA sequencing solutions used across scientific research and public health applications. Founded in 2005 as a spin-out from the University of Oxford, the business provides technology to characterise pathogens and advance biomedical science.
Categories
Team
GS
Gordon Sanghera
CEO
Gordon serves as CEO and founder of Oxford Nanopore Technologies. His background includes a role as R&D Director at Abbott Diabetes Care and research experience at the University of Oxford.
LinkedInInvestors
- £195M
- £84.4M
Funding history
£84.4M
The financing round draws participation from International Holdings Company, RPMI Railpen and RT Puhua Genomics.
£29.3M
The company secured new capital from international investors across the US, Europe, and Asia.